Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
L218CAR19 in Relapsed/Refractory B-cell Lymphomas
NCT06478381Phase 1Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jun 2024
- Primary completion
- Dec 2025
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of L218CAR19 in B cell lymphoma, sponsored by Henan Cancer Hospital. Primary endpoints: Dose Limiting Toxicity at 4 weeks and Treatment-Emergent Adverse Events at 1 year. Started Jun 2024; status: recruiting.
02
Drugs
L218CAR19
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT06478381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06478381.